Anchor Capital Advisors’s AstraZeneca AZN Stock Holding History

Anchor Capital Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.45M	Sell	49,828 -4,935	-9%	-$928K	0.27%	87
2026 Q1	$10.8M	Sell	54,763 -909	-2%	-$175K	0.31%	88
2025 Q4	$10.2M	Sell	55,672 -1,503	-3%	-$264K	0.3%	91
2025 Q3	$8.77M	Sell	57,175 -1,057	-2%	-$160K	0.25%	95
2025 Q2	$8.14M	Sell	58,232 -21,322	-27%	-$2.99M	0.24%	99
2025 Q1	$11.7M	Sell	79,554 -3,160	-4%	-$457K	0.35%	93
2024 Q4	$10.8M	Sell	82,714 -795	-1%	-$111K	0.31%	97
2024 Q3	$13M	Sell	83,509 -1,386	-2%	-$224K	0.35%	95
2024 Q2	$13.2M	Sell	84,895 -177	-0.2%	-$26.6K	0.37%	94
2024 Q1	$11.5M	Sell	85,072 -8,547	-9%	-$1.13M	0.3%	98
2023 Q4	$12.6M	Sell	93,619 -2,359	-2%	-$307K	0.33%	90
2023 Q3	$13M	Sell	95,978 -2,403	-2%	-$328K	0.36%	85
2023 Q2	$14.1M	Buy	98,381 +11,481	+13%	+$1.69M	0.37%	84
2023 Q1	$12.1M	Buy	+86,900	New	+$11.7M	0.32%	89

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Anchor Capital Advisors's AZN Position: Q2 2026 in Review

Anchor Capital Advisors reduced its AstraZeneca (AZN) stake by 9% in Q2 2026, selling an estimated $928K and leaving 49,828 shares worth $9.45M. The position accounts for 0.27% of the portfolio, ranked #87.

Anchor Capital Advisors first reported a position in AZN in Q1 2023 and has held it in 14 quarters since. The position peaked at $14.1M in Q2 2023. 1,498 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Anchor Capital Advisors held 49,828 shares of AstraZeneca worth $9.45M as of Q2 2026.
Anchor Capital Advisors sold 4,935 AstraZeneca shares in Q2 2026, an estimated $928K.
AstraZeneca made up 0.27% of Anchor Capital Advisors's portfolio in Q2 2026, its #87 holding.
Anchor Capital Advisors first reported a position in AstraZeneca in Q1 2023 and has held it in 14 quarters since.
Anchor Capital Advisors's AstraZeneca position peaked at $14.1M in Q2 2023.
1,498 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Anchor Capital Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.